Companies / Maplight Therapeutics Inc
Maplight Therapeutics Inc
Nasdaq: MPLTCIK 1770069REDWOOD CITY, CA
Financials
Ownership
45.3M shares outstanding · as of May 7, 2026
Ownership
Share classes
| Common Stock | 93.99% | |
| Common Stock | 6.01% |
| Insiders | 6.20% | 2,813,318 |
| 10%+ / strategic | 6.17% | 2,799,180 |
| Institutions | 46.85% | 21,244,544 |
| Public float | 40.77% | 18,488,634 |
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 10
View all →| Insider | % of shares | Shares |
|---|---|---|
Kroeger Christopher A.CEOChief Executive Officer · Director | 3.64% | 1,649,751 |
Foff Erin PennockChief Medical Officer | 0.89% | 403,835 |
Setia VishwasChief Financial Officer | 0.87% | 395,549 |
Malenka Robert C.Director | 0.72% | 325,059 |
Lillie James WoodruffFormerChief Scientific Officer | 0.66% | 298,862 |
Kreitzer AnatolFormerChief Discovery Officer | 0.57% | 259,928 |
Gillis JonathanFormerCAAO and PAO | 0.56% | 254,523 |
Hanson KristopherFormerGeneral Counsel | 0.42% | 191,582 |
Pavlov GeorgeDirector | 0.06% | 25,000 |
Garnett Timothy JohnDirector | 0.03% | 14,124 |
Institutional holders 81
View all →| Holder | Value | % of shares |
|---|---|---|
| $74.95M | 8.13% | |
| $56.67M | 7.12% | |
| $36.74M | 2.26% | |
| $34.03M | 4.27% | |
| $30.54M | 1.88% | |
| $18.54M | 2.01% | |
| $17.06M | 2.14% | |
| $16.69M | 2.10% | |
| $15.28M | 1.92% | |
| $10.74M | 1.35% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q2 2026 as of | State Street Corporation 13F manager | Add | Common Stock | $22.32M | +623K +271.33% | 852,150 1.88% of shares | medium |
| Q1 2026 as of | Perceptive Advisors LLC 13F manager | Exit | Common Stock | $-9.66M | -550K -100.00% | 0 | medium |
| Q1 2026 as of | RA Capital Management, L.P. 13F manager | New | Common Stock | $5.05M | +248K | 248,294 0.55% of shares | medium |
| Q2 2026 as of | BlackRock, Inc. 13F manager | Trim | Common Stock | $-2.52M | -70K -6.42% | 1,025,134 2.26% of shares | low |
| Q1 2026 as of | Geode Capital Management, LLC 13F manager | Add | Common Stock | $1.87M | +92K +23.69% | 481,201 1.06% of shares | low |
| Q1 2026 as of | Lazard Asset Management LLC 13F manager | Trim | Common Stock | $-1.33M | -65K -31.56% | 142,016 0.31% of shares | low |
| Q1 2026 as of | Janus Henderson Group PLC 13F manager | New | Common Stock | $1.11M | +55K | 54,752 0.12% of shares | low |
| Q1 2026 as of | Orbimed Advisors LLC 13F manager | Exit | Common Stock | $-952.0K | -56K -100.00% | 0 | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Forbion Growth Opportunities Fund III Cooperatief U.A. | Passive13G | — |
| T. Rowe Price Investment Management, Inc. | Passive13G | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| MPLT | Common Stock | 56565P103 |